Published in Cancer Weekly, September 16th, 2003
In the 11-year study of 307 patients, conducted by the Southwest Oncology Group (SWOG) and led by an investigator at the University of Texas M.D. Anderson Cancer Center, researchers found that patients who received neoadjuvant chemotherapy lived an average of 31 months longer, and that those treated with surgery alone had a 66% greater chance of dying from bladder cancer than patients who had the combination therapy. The findings were published in the New...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.